Innovative Industrial Properties, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IIPR research report →
Range $56.25 – $56.25
Price Chart
About the company
Innovative Industrial Properties, Inc. is an independently managed, Maryland-based corporation primarily focused on acquiring, owning, and overseeing unique real estate assets. These properties are subsequently leased to experienced, state-licensed operators who utilize them for their regulated medical cannabis facilities.
- CEO
- Paul E. Smithers
- IPO
- 2016
- Employees
- 24
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on IIPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.39B
- P/E
- 11.20
- Fwd P/E
- 11.59
- PEG
- 2.41
- P/S
- 5.28
- P/B
- 0.75
- EV/EBITDA
- 7.81
- Div Yield
- 15.05%
- Gross Margin
- 60.61%
- Op Margin
- 51.34%
- Net Margin
- 53.20%
- ROE
- 7.56%
- ROIC
- 5.34%
Latest fiscal year · YoY change
- Revenue
- $265.95M-13.8%
- Gross Profit
- $235.78M-15.8%
- Op Income
- $124.12M
- Net Income
- $114.44M-29.2%
- EPS
- $3.98-28.7%
- OCF Growth
- -23.3%
- FCF Growth
- -32.4%
- Beta
- 1.38
- RSI (14)
- 32
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IIPR delivered higher quarterly AFFO on rent recoveries and leasing, while continuing to diversify into life science with new capital commitments and strong liquidity.· November 3, 2026
- AFFO per share rose 7% sequentially to $1.96, helped by recoveries of past-due rents and new leasing activity.
- Quarterly revenue increased to $64.9 million from $63.3 million in the prior quarter.
- The company expanded life science exposure with $275 million in new commitments, including a $245 million IQHQ mezzanine loan and a $30 million preferred investment.
- Leasing activity was a quarterly record at 604,000 square feet, plus another 270,000 square feet signed after quarter end.
- Balance sheet remained conservative with $142 million of liquidity at quarter end and net debt to adjusted EBITDA of 2.1x.
Third-quarter revenue was $64.9 million, versus $63.3 million in the second quarter. AFFO totaled $54.8 million, or $1.96 per diluted share, versus $53.0 million, or $1.83 per diluted share, in the prior quarter. Management said the quarter benefited from new leases and recoveries of past-due rents, with Battle Green contributing $0.15 per share, and total interest and other income reached $14.3 million, including $10.4 million from IQHQ-related interest and dividend income. No full-year or next-quarter guidance was provided; instead, management highlighted expected additional benefit in Q4 from the Alewife investment, ongoing lease-up and rent recoveries, and continued capital deployment into life science.
Alan D. Gold emphasized execution across both the legacy cannabis portfolio and the expanding life science platform. He said the company sees compelling opportunities to deploy capital into life science at attractive entry points, highlighted the $245 million Alewife Park mezzanine commitment and the $30 million preferred investment, and said life science investments could represent about 26% of total annualized income upon full funding. His tone was constructive and confident, framing diversification as both a growth strategy and a way to broaden access to capital.
David J. Smith focused on the quarter’s financial improvement and balance sheet strength. He cited revenue of $64.9 million, AFFO of $54.8 million, and liquidity of $142 million at quarter end, while noting that the company also added $54 million of gross proceeds from a Series B preferred offering after quarter end. He said net debt to adjusted EBITDA was 2.1x and net debt to total gross assets was 19%, and noted the company extended its $87.5 million revolving credit facility by 90 days to January 2027.
Analysts pressed management on how long it may take to re-lease recovered properties and whether AFFO can stay above the $1.90 dividend level. Management said re-tenanting can take 6 to 18 months, that Florida represents about two-thirds of current vacancy, and that year-to-date re-tenanting costs have been well below $10 per square foot all-in. They also explained that some third-quarter AFFO benefits were nonrecurring, but said they have historically done a good job recovering past-due rent. Questions on IQHQ centered on whether the company would buy the additional $155 million mezzanine tranche and whether there is room for more investment; management said it is a possibility if capital is available and that the board remains open to additional life science opportunities.
The call showed improving operating momentum: record leasing, faster-than-expected rent recoveries, and a higher AFFO run rate. Management also sounded upbeat about life science, pointing to strong demand in core markets, attractive returns on the IQHQ deal, and more financing flexibility from preferred capital and lender interest.
A meaningful part of the quarter’s AFFO was supported by recoveries and other items management described as nonrecurring, so sustainability remains a question. The company still has over 800,000 square feet of vacancy, re-tenanting can take 6 to 18 months, and the timing of federal cannabis reform remains uncertain despite positive headlines.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.9%
- Shares Outstanding
- 27.57M
- Float Shares
- 26.99M
of shares held by institutions
344 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for IIPR, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.92M | ▼ 76.73K |
| Vanguard Group Inc | 4.27M | ▲ 4.23K |
| Vanguard Portfolio Management LLC | 2.80M | ▼ 23.59K |
| State Street Corp | 1.61M | ▼ 19.86K |
| Vanguard Capital Management LLC | 1.24M | ▼ 51.18K |
| Mirae Asset Global Etfs Holdings Ltd. | 779.51K | ▲ 255.32K |
| Charles Schwab Investment Management Inc | 620.44K | ▼ 28.16K |
| Invesco Ltd. | 554.14K | ▲ 56.68K |
| Northern Trust Corp | 387.77K | ▼ 8.22K |
| Dimensional Fund Advisors LP | 374.71K | ▲ 9.93K |
| Arrowstreet Capital, Limited Partnership | 320.81K | ▼ 243.50K |
| Goldman Sachs Group Inc | 310.08K | ▼ 52.65K |
Held by 404 ETFs
Biggest fund positions in IIPR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 26 | Gold Alan D | buy | 40,000 |
| Sep 15, 26 | Shoemaker Scott | sell | 611 |
| Aug 31, 26 | Ives Bruce Alan | buy | 528 |
| Jun 19, 26 | Gold Alan D | other | 33,960 |
| Jun 19, 26 | Smith David Jon | other | 9,219 |
| Jun 19, 26 | Smithers Paul E. | other | 22,299 |
| Jun 9, 26 | Ives Bruce Alan | other | 2,652 |
| Jun 9, 26 | Ives Bruce Alan | other | 0 |
| Jun 9, 26 | Shoemaker Scott | other | 2,652 |
| Jun 9, 26 | Boyle David Gerard | other | 2,652 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IIPR coverage
Recent articles, reports, and earnings notes.
No research on IIPR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IIPR report →